Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab or Nivolumab in Patients with Advanced Solid TumorsPhase IB trial of rpt dose TRX518 singly…

Overview of attention for article published in Clinical Cancer Research, May 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 17 X users

Readers on

mendeley: 25 Mendeley

Summary X

So far, Altmetric has seen 25 X posts from 17 X users, with an upper bound of 35,923 followers.

IMMUNOTHERAPY: a GITR-targeting mab was well tolerated and resulted in immune cell activation in a phase 1 study; however, single agent activity was poor (ORR 4%). https://t.co/CDCNFqqSeP

23 Sep 2022

Reply Repost Favourite

Phase 1b Study: GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab. https://t.co/5lRmlJRZ5i https://t.co/UyGOFNrkin

22 Sep 2022

Reply Repost Favourite

PALOMA-2のOSはmetしなかったけど、PALOMA-3のOSはimproved？（リンク先がまちがってますがな…orz

17 Jun 2022

Reply Repost Favourite

RT @CCR_AACR: Updated exploratory analysis of the PALOMA-3 clinical trial shows improved #OverallSurvival with #palbociclib plus #fulvestra…

17 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 21 additional X posts.